The purpose of this study was to compare the response assessments using RECIST 1.1, mRECIST, and iRECIST and to evaluate the correlation between survival outcome and response assessment achieved by these criteria in HCC treated with PD-1 inhibitor. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.